Market Place
Sourcing Support
Astria Therapeutics to Present at Jefferies London Healthcare Conf.
13 Nov 2024 //
BUSINESSWIRE
Astria Therapeutics Reports Q3 2024 Results & Corporate News
13 Nov 2024 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Nov 2024 //
BUSINESSWIRE
Astria Therapeutics to Present at Canadian Allergy Meeting
30 Oct 2024 //
BUSINESSWIRE
Astria Therapeutics Presents At Allergy And Immunology Meeting
21 Oct 2024 //
BUSINESSWIRE
EU Grants Orphan Designation For Navenibart In Hereditary Angioedema
16 Oct 2024 //
BUSINESSWIRE
Astria Therapeutics Announces Inducement Grants Under Nasdaq Rule
02 Oct 2024 //
BUSINESSWIRE
Astria`s Navenibart Receives FDA Orphan Drug Designation
30 Sep 2024 //
BUSINESSWIRE
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
27 Sep 2024 //
BUSINESSWIRE
Astria Therapeutics To Present At Upcoming EADV Congress
19 Sep 2024 //
BUSINESSWIRE
Astria Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
04 Sep 2024 //
BUSINESSWIRE
Astria Therapeutics to Present at Upcoming Bradykinin Symposium
30 Aug 2024 //
BUSINESSWIRE
Astria Therapeutics To Attend Morgan Stanley Healthcare Conference
29 Aug 2024 //
BUSINESSWIRE
Astria Chooses Ypsomed`s YpsoMate For STAR-0215 HAE Treatment
12 Aug 2024 //
BUSINESSWIRE
Astria Reports Q2 2024 Results And Provides Corporate Update
12 Aug 2024 //
BUSINESSWIRE
Astria Therapeutics To Participate In Wedbush PacGrow Healthcare Conference
07 Aug 2024 //
BUSINESSWIRE
Astria Therapeutics Announces Inducement Grants Under Nasdaq Rule
02 Aug 2024 //
BUSINESSWIRE
Astria Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
02 Jul 2024 //
BUSINESSWIRE
Astria Therapeutics: Announces Nasdaq Inducement Grants
04 Jun 2024 //
BUSINESSWIRE
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
30 May 2024 //
BUSINESSWIRE
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
24 May 2024 //
BUSINESSWIRE
Astria Allergy Congress Details: European Immunology Presentation Upcoming
23 May 2024 //
BUSINESSWIRE
Astria Therapeutics Q1 2024 Financials, Corporate Update
09 May 2024 //
BUSINESSWIRE
Astria Therapeutics: Society for Investigative Dermatology Meeting Presentation
08 May 2024 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq Listing Rule
02 May 2024 //
BUSINESSWIRE
Astria Thera Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2024 //
BUSINESSWIRE
With new data in hand, Astria makes ph. 3 wish on shooting star
25 Mar 2024 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Mar 2024 //
BUSINESSWIRE
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
04 Mar 2024 //
BUSINESSWIRE
Astria to Present at American Academy of Allergy & Immunology Annual Meeting
20 Feb 2024 //
BUSINESSWIRE
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Conference
06 Feb 2024 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Feb 2024 //
BUSINESSWIRE
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
30 Jan 2024 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Dec 2023 //
BUSINESSWIRE
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
27 Nov 2023 //
BUSINESSWIRE
Astria Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
21 Nov 2023 //
BUSINESSWIRE
Astria Therapeutics Reports Third Quarter Financial Results
13 Nov 2023 //
BUSINESSWIRE
Astria Therapeutics Presents Phase 1a Data Confirming Potential for STAR-0125
10 Nov 2023 //
BUSINESSWIRE
Astria Therapeutics to Present at Jefferies London Healthcare Conference
09 Nov 2023 //
BUSINESSWIRE
Astria Therapeutics to Present New STAR-0215 Data at Scientific Meeting
03 Nov 2023 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Nov 2023 //
BUSINESSWIRE
Astria Therapeutics to Report Third Quarter 2023 Financial Results
30 Oct 2023 //
BUSINESSWIRE
Ichnos Sciences inks agreement with Astria Therapeutics for OX40
13 Oct 2023 //
INDIAN PHARMA POST
Astria pays Ichnos $15M to join eczema race led by Amgen, Sanofi
12 Oct 2023 //
FIERCE BIOTECH
Astria Announces Exclusive Worldwide License Agreement with Ichnos Sciences
11 Oct 2023 //
BUSINESSWIRE
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
11 Oct 2023 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2023 //
BUSINESSWIRE
Astria Therapeutics to Participate in Upcoming Investor Conferences
06 Sep 2023 //
BUSINESSWIRE
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data
31 Aug 2023 //
BUSINESSWIRE
Astria to Present Patient Survey Data at 2023 HAEi Regional EMEA Conference
25 Aug 2023 //
BUSINESSWIRE
Astria Therapeutics Reports Second Quarter Financial Results
07 Aug 2023 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2023 //
BUSINESSWIRE
Astria Receives Fast Track Designation for STAR-0215 for Treatment of HAE
20 Jul 2023 //
BUSINESSWIRE
Astria Therapeutics Names John Ruesch as Senior Vice President
17 Jul 2023 //
BUSINESSWIRE
Astria Therapeutics to Present Patient Survey Data at 2023 HAEA National Summit
14 Jul 2023 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Jul 2023 //
BUSINESSWIRE
Astria Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Jun 2023 //
BUSINESSWIRE
Astria Therapeutics to Present STAR-0215 at the 2023 Immunology Annual Meeting
05 Jun 2023 //
BUSINESSWIRE
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
31 May 2023 //
BUSINESSWIRE
Astria Therapeutics Reports First Quarter Financial Results
11 May 2023 //
BUSINESSWIRE
